Lenalidomide-Associated ITP
Lenalidomide is a potent immunomodulatory agent being used increasingly for treatment of hematologic malignancies including multiple myeloma and myelodysplasia. The common toxicities of lenalidomide, including dose-limiting myelosuppression, are well described. However, the immunomodulatory properti...
Saved in:
Main Authors: | Christina I. Herold, Cristina Gasparetto, Gowthami M. Arepally |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2011-01-01
|
Series: | Case Reports in Hematology |
Online Access: | http://dx.doi.org/10.1155/2011/638020 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
An Unusual Cause of Secondary ITP in a 34-Year-Old Hispanic Male
by: Ayrton Bangolo, et al.
Published: (2021-01-01) -
Successful Control of Acute Myelofibrosis with Lenalidomide
by: G. Vassilopoulos, et al.
Published: (2010-01-01) -
RITUXIMAB VERSUS SPLENECTOMY IN CHRONIC PRIMARY ITP: EXPERIENCE OF A SINGLE HEMATOLOGY CLINIC
by: Rawanda Shamoon, et al.
Published: (2024-02-01) -
Lenalidomide-Associated Immune Thrombocytopenia: A Case Report and Review of the Literature
by: William Forehand III, et al.
Published: (2020-01-01) -
Immune Thrombocytopenic Purpura (ITP) as an Uncommon Extraintestinal Complication of Crohn’s Disease: Case Vignette and Systematic Literature Review
by: Raisa Epistola, et al.
Published: (2020-01-01)